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Quality Improvement in the management of people with epilepsy and 






This clinical guidance looks at the specific concerns of delivery of medical treatment for people with 
epilepsy and intellectual disability (ID). People with ID have not been included in licencing drug trials 
of AEDs. However, this population has an over representation of seizure comorbidity, trea ment 
resistance and polypharmacy while also being vulnerable to not having their views considered.   
Areas Covered 
This review summarises the current most robust evidence available for the use of lic nced AEDs 
people with epilepsy and ID.  The article will provide practical evidenced based clinical information 
to help prescribers choose the most appropriate AED from the drugs discussed. The article highlights 
other important individualised factors to consider before initiating or changing antiepileptic 
medication. 
Expert Opinion 
A ‘traffic light’ coding system is applied to commonly used AEDs based on the level of evidence and 
expert clinical experience. Managing epilepsy in the ID population requires specialist care.  Treatment 
plans need to be holistic and tailored to accommodate an individual’s co-morbidities, concurrent 
medications, general health, social and environmental status. There is a need for large quality trial 







There has been a firm and sustained ‘call for action’ to improve the delivery of care to people with 
epilepsy and intellectual disability (ID) in the UK and other parts of the world.  In 2014 the Task 
Force on epilepsy and ID of the International League against Epilepsy (ILAE) published a White 
Paper that proposed a framework to enhance the delivery of supports for people with epilepsy and ID 
and identified four major areas of concern [1]. One of them related to the diagnosis and medical 
treatment of people with epilepsy and ID (Table 1). Specific concerns were identified in relation to 
the prescription and monitoring of antiepileptic drugs (AEDs), particularly the associated side effects. 
The recommended actions from the White Paper included the need for a position paper est blishing 
best practice in the identification and monitoring of side effects associated with AEDs, with specific 
attention to be paid to drug interactions [1].   
Table 1: Areas of concern in the Diagnosis and Medical Treatment of people with epilepsy 
and ID [1] 
 
▪ Misdiagnosis - complexity of presentation and co-morbidities  
▪ Communication during consultation 
▪ Challenges in accessing appropriate investigations 
▪ Medication concerns - side effects, monitoring treatment success 
▪ Transfer of knowledge between all stakeholders 
▪ Availability of accessible information 
 
1.1 Epilepsy and ID 
The prevalence of epilepsy in the general population has been reported to be between 0.6 and 1% [2].  
In contrast, up to one-quarter of individuals with ID will have a diagnosis f epilepsy and the 
prevalence of epilepsy increases with the severity of ID [3]. Many people with epilepsy and ID show 
a poor response to AEDs [4]. Treatment resistant epilepsy (defined as failure of adequate trials of two 
tolerated and appropriately chosen and used AEDs [5]), ID, and neurological deficitsuggest a 
multifactorial aetiology and are often associated with multiple physical and psychological                  
co-morbidities [6, 7]. In order to address the barriers the ID population face in receiving appropriate 
seizure care, we need to first understand the complexity of presentation and indiviual needs of 
people with ID (Table 2). As epilepsy is such a common c -morbidity for people with ID, many 
doctors involved in the care of people with ID are also involved in the assessment and treatment of 
seizures in people with ID. Those who are not directly involved must have a basic understanding of 
the impact seizures and its treatment may have on an individual holistically, specifically regarding 
mental health and behaviour [8, 9]. 
Table 2: The complexity of epilepsy in the ID population [8] 
        Seizures are usually present in early life 
        Higher rates of  genetic/structural brain damage  
        Higher rates of generalised seizures 
        Lower rates of seizure freedom with first AED treatment 
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        More likely to have life-long seizures 
Higher rates of SUDEP/status epilepticus 
Higher rates of AED prescription and polypharmacy 
More likely to be prescribed and to use rescue medication 
Increased rates of Emergency Department attendance because of seizures 
Multiple co-morbidities common 
Communication, choice, and capacity complexities 
Difficult to measure treatment success 
Specific issues with chewing, swallowing problems, constipation, and percutaneous endoscopic 
gastrostomy (PEG) feeding 
2.0. The development of clinical guidance 
 
 
In 2017 in the UK, Faculty of Psychiatry of Intellectual Disability of the Royal College of 
Psychiatrists developed a strategic response to address some of the identified concerns.  The first step 
was to develop a tiered model (Bronze, Silver, and Gold) of professional competencies for 
psychiatrists working with people with epilepsy and ID.  While directed at Psychiatrists i  can be an 
apt template for any professional group which indulges in managing people with epilepsy and ID.   
Each category of competency is aligned to the National Institute of Health and Care Excellence 
(NICE) outcome indicators for epilepsy and the Scottish Intercollegiate Guidelines Network (SIGN) 
guidance.  Bronze level competency is the minimum expected standard for all psychiatri ts in ID on a 
continuum that extends to more expert care encompassed in the silver and gold competencies.  Bronz  
competency is focused on the basic management of epilepsy, encompassing diagnosis and treatment 
(non-complex), effects of treatment and associated side-effects, and awareness and mitigation of 
direct and indirect risks associated with ID and epilepsy.  The development and approach to 
application of this model is set out in the RCPsych College Report (CR203), good practice guidance 
on the management of epilepsy in adults with intellectual disability [9]. 
The next step in the Faculty’s strategic response was the development of a position statement for the 
prescription of AEDs for people with epilepsy and ID, as called for by the ILAE White paper (Kerr et 
al, 2014).  The scope of the position paper was to establish best practice for th  management of 
epilepsy with AEDs and the identification of their side effects.  Specific attention is paid to drug-drug 
and drug-disease interactions because of the high level of co-morbid conditions and associated 
polypharmacy experienced by this population, particularly the associated mental h alth conditions.  
This summary of the evidence was designed to help inform prescribing clinicians in relation to the 
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attaining of the Bronze/Silver/Gold competencies laid out in the College Report (CR203) [9].  The 
full scope of this report is collated in in the RCPsych College Report (CR206) [8]. 
The working group of the International Society for the Scientific Study of Intellectual and 
Developmental Disorders (IASSIDD) has developed consensus guidelines on the management of 
epilepsy in adults with ID [10].  However, to date there are no specific national guidelines for the 
management of epilepsy in people with ID in the UK (or any other countries that we are aware of), 
and of specific relevance none that relate to the professional grouping of doctors who work with 
people with ID.  Both NICE and SIGN recognise the complexities associated with prescribing to this 
group but there is a limited evidence base [11].  Cochrane reviews examining pharmacologic l 
interventions for epilepsy in people with ID highlight the lack of high-quality evidence examining the 
efficacy, side-effect profile, and safety of AEDs for people with ID [12, 13].  The complexity of 
presentation of epilepsy with ID warrants specific considerations, particularly the potential for adverse 
effects of AED treatment upon cognition and behaviour.  As a result of the limited robust research 
available, the choice of medication is largely based upon data extrapolated from trials in the general 
population with epilepsy.  There is more robust evidence to guide decisions around prescribing in a 
few specific seizure syndromes (epileptic encephalopathies) associated with the development of ID 
including Lennox-Gastaut and Dravet syndromes [13, 14, 15].   
There is a strong case for the delivery of guidance specific to psychiatric prctice for the management 
of epilepsy in people with an ID. This paper outlines the methodology and key content of these 
guidelines. 
 
2.1 Strategic response to improve quality of care 
 
A working committee was formed from members of the Faculty of Psychiatry of ID Executive 
Committee.  The Executive Committee consists of elected representatives and co-opted members of 
the Faculty.  The working group included doctors with a primary role of supporting people with ID 
with a range of experience in epilepsy.  Special advisors such as neurologists and nurses with 
expertise in epilepsy were identified to support the group.  Objectives for the strategy were discussed 
and set by the working group (Table 3). 
 
Table 3: Objectives-set by the working group 
• To identify the current evidence base on prescribing AEDs to people with ID.  • To identify the general and specific needs and requirements of people with ID wo have epilepsy 
focusing on the impact of AEDs. • To identify and deliver a matrix to evaluate current AEDs to combine evidence and expert 
clinician perspective.  • To identify a prescribing framework for doctors to use while managing or consulting to a person 
with ID and epilepsy. • To provide an overview of the side effect complexity and how to mitigate them. • To highlight the practical pitfalls in co-prescribing with other medication particularly 
psychotropics. • To consider using to self-measure and develop epilepsy competencies as proposed in  the  
epilepsy strategy document (CR203) [9] 
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• To provide a template for a national dialogue with Epilepsy Specialist Nurses, Neurologists and 
GPs to develop a unified strategy to improve outcomes in epilepsy for people with ID.  
A comprehensive literature search was conducted based upon a recent review article conducted to 
investigate AED treatment in adults with ID [11].  The working group considered National guidance 
and best practice documents from NICE, SIGN, and the recent ILAE White Papers on epilepsy and 
ID.  The evidence in the report is not a systematic review of the literature.  The working group ar ived 
at a consensus on the most appropriate evidence to include within the guidance as a resource of 
examples for clinicians.   
The evidence available for each AED was graded according to the criteria set out by the Canadian 
Task Force on the Periodic Health Examination (1979) [16].  The working group propose a rating 
system for current AED medication using a ‘traffic light’ coding system.  The ‘traffic-light’ coding 
for each AED was agreed by consensus of the working group based on current evidence, clinical 
experience, and expert views from the field.   
A draft document was circulated to the working committee and a wider group of identified experts in 
the field external to the ID Faculty, including three expert neurologists specialising in epilepsy, two 
academics, one epilepsy specialist nurse, two specialists in ID and epilepsy, one general practitioner 
with special interest in epilepsy, one pharmacist, one psychiatrist in General Adult Psychiatry and 
three psychiatrists in Psychiatry of ID. A first round of extensive feedback was gathered and 
assimilated into the document.  
An update on the planned structure of the document was presented to the Faculty of Psychiatry of ID 
Executive Committee.  Approval was gained to continue in the direction identified and specific issues 
were highlighted.  The report was circulated for a second round of reviews to all members of the 
working group and invited experts.  On completion of this process, the report was submitted to the 
Royal College of Psychiatrists oversight committee for review and quality assurance.  As part of the 
larger College review the document was circulated for feedback to all its other faculties and special 
interest groups. A third round of feedback was received from the Psychopharmacology C mmittee, 
Neuropsychiatry Committee,  the Northern Ireland Division  a d the Faculty of Old Age Psychiatry   
and incorporated  into the final report document (CR206) [8] Alongside feedback was also collected 
from the ILAE British Chapter. 
2.2 Choosing the most appropriate AED 
 
From the data available for commonly prescribed AEDs in people with ID the results were graded by 
a traffic light system integrating research evidence on efficacy, side effect profile, and safety 
alongside clinical experience from experts in the field.  The information was synthesised and 
presented in an accessible format for prescribers to easily access when weighing up prescribing 
choices in complex clinical scenarios (Table 4).  This data provides information of the AEDs with the 
most robust evidence and should not be considered as exclusive. 
RED – Only use in exceptional circumstances 
AMBER- Could be considered if benefits outweigh risks or as second line 
GREEN- Needs to be considered as first line treatment 
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et al 2001 
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especially if used in 
conjunction with 
diuretics or SSRIs 
Phenytoin  none None  - V Red 
Unsuitable due to –
• Multiple drug 
interactions • behavioural 
side effects • needs for 
regular blood 
monitoring 
Any consideration of 
Phenytoin needs a 
comprehensive 
discussion with patient 
of the benefits and risks 
of using this medication 
weighed in balance to 
other alternatives, 
efficacy and side 
effects. 
 
Phenobarbitone none none - V Red 
Unsuitable due to –
• Cognitive 
issues • Multiple drug 
interactions • behavioural 




Any consideration of 
phenobarbitone needs a 
comprehensive 
discussion with patient 
of the benefits and risks 
of using this medication 




efficacy and side 
effects. 
 
*In 2018 the Medicines and Healthcare products Regulatory Agency (MHRA) reviewed the 
guidance on valproate medicines.  Valproate containing medicines are contraindicated in girls 
or women of child bearing age unless they participate in the Pregnancy Prevention 
Programme. 
 
2.22 Other AEDs 
To date, the evidence for the safety, tolerability and efficacy of other AEDs in people with ID 
including pregabalin, tiagabine, stiripentol, eslicarbazapine, oxcarbazepine, retigabine, 
euthosuximide, and zonisamide is limited.  There are specific epilepsy syndromes and epileptic 
encephalopathies where some of these AEDs are used under specialist supervision that i  beyond the 
scope of this review. 
 
2.23 Rescue Medication 
 
Benzodiazepines e.g. buccal (oromucosal) midazolam are widely used as emergency rescue 
medication and there is good supporting evidence for their use.  The prescription of buccal midazo am 
should be accompanied by specific strict guidelines on how and when to administer and be review d 
regularly.  Midazolam is specifically used to help halt seizures in the community and is especially 
useful due to its buccal administration [32].  Clobazam is a u eful adjunct for short periods to manage 
clusters of seizures [33].  Best practice guidelines for the treatment of prolonged/clusters of epileptic 
seizures in the community has been published by ESNA (Epilepsy Nurses Association) in association 
with the ILAE and RCPsych and should be followed. There are several cautions to consider when 
prescribing benzodiazepines for epilepsy including the potential negative effects on cognition, 
potential for sedation, and possible tolerance to the drugs [34]. 
3.0 Conclusion 
 
The management of epilepsy in people with ID needs to be individualised and based on a good 
understanding of the combination of factors related to ID and those related to epilepsy.  The first 
principle of epilepsy management should be patient safety.  Two key risk areas to be considered are 
bathing and sudden unexpected death in epilepsy (SUDEP).  Every individual should have a 
personalised epilepsy care plan including a formal assessment of risk that is reviewed regularly.  A 
holistic assessment of the person, their condition, their specific risks and an appropriate treatmen  pl n 
for both rescue medication and regular treatment needs to be produced, understood, and 
communicated to all clinicians and carers.  Evidence about the effectiveness of treatment and the 
potential side effects is not as good as desired but the limited evidence should be applied in clinical 
practice.  The evidence gained from RCTs may not be generalizable to this population. Because of the 
lack of evidence in this group of people, it is sometimes necessary to extrapolate fr m the evidence in 
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the general population with epilepsy.  In the future pragmatic study designs may help provide more 
specific evidence to guide treatment choices.  Side effects of medication may present as changes in 
behaviour in people with ID as they may find is difficult to express the changes they feel due to 
impairments in communication. Baseline recordings of an individual’s usual presentation, routine, and 
behaviours helps to mitigate for this.  While not a focus of this review thought needs to be given to the 
role of a ketogenic diet and/or a vagus nerve stimulator and its part as adjunct to AEDs.  All treatment 
should be about improving the Quality of Life (QoL) of the person. Consideration could be given to 
developing a trusting relationship with the patient/carer and where possible ensure QoL discussions is 
supported by evidence based frameworks such as The International Classification of Functi ning, 
Disability and Health (ICF). This is a classification of health and health-re ated domains. As the 
functioning and disability of an individual occurs in a social and environmental context this can 
influence treatment outcomes significantly. The best improvement in QoL is achieved through seizure 
reduction, but this cannot be at the cost of intolerable side effects.  When there is worsening in se zure 
control or difficulty in gaining control of seizures thought needs to be given to the physical health,  
psychological, social, environmental and any care aspects of the individual. Changes in these can 
significantly influence the seizure domain.   
 
4.0 Expert Opinion 
 
The National Institute for Clinical Excellence (NICE) Clinical Guideline on Epilepsies (CG137) 
considers the challenges of diagnosing epilepsy in people with ID (NICE, 2012) [35].  Establishing 
seizure activity is complex owing to the increased frequency of physical and neuropsychiatric          
co-morbidities, and impaired communication.  There is a strong association with neurodevelopment 
disorders such as Autism which may be associated with stereotypical behaviours that can mimic 
seizure activity.  The ILAE clinical definition for epilepsy should be followed [36] and where possible 
clinicians should attempt to identify seizure type, epilepsy type, and epilepsy syndrome [37].   
When initiating AEDs for people with ID, a good guiding principle is to start at a low dose and titrate 
slowly (Table 5).  The initial dose may be far below the guidance for dose titration in the general 
population and may not achieve a therapeutic level for some time.  This process will reduce the risk of 
dose-related adverse effects.  It also allows for ready identification of the ‘therapeutic window’.  The 
lowest efficacious dose will also minimise the likelihood of side eff cts.  A drug should not be 
considered ineffective unless a therapeutic dose has been reached.  This should, however, not be at the 
cost of intolerable side effects. When adding a ‘new’ AED, good practice dictates that the new drug is 
added before the old drug is removed.   This minimises confusion around symptoms and changes in 
seizures or side effects during the titration phase of the added drug.  As discu sed, many people with 
ID and epilepsy have treatment resistant seizures and therefore the situation is m re complex with 
multiple AEDs.  However, the principle of caution should be adopted when prescribing.   
Table 5: Other considerations when prescribing AEDs for people with ID developed by working 
group for the RCPsych CR206 [8] 
AED side effect profile Neuropsychiatric effect/behaviour: 
-Behavioural changes are often multifactorial with a wide range of 
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influencing factors outside the prescription of AEDs   
-Any change in behaviour requires thorough assessment from a variety 
of professionals, especially  in the context of co-morbid 
neurodevelopment disorder such as Autism 
-It is appropriate to establish a baseline of behaviour and detailed 
history before AED introduction 
-AED introduction at low dose with slow titration will help reduce  
possible adverse neuropsychiatric effects 
Cognition: 
-AED effects on cognition may be acute and are usually dose-related 
-Older AEDs with poor cognitive profiles such as phenobarbitone and 
phenytoin should be avoided where possible 
-Lamotrigine appears to demonstrate a positive cognitive profile 
Weight 
Weight gain-valproate, gabapentin, pregabalin, levetiracetam (atypical) 
Weight loss-topiramate, zonisamide 
Bone Density: 
-People with epilepsy and ID are at high  risk of lowered bone density 
[38]  
-Long term use of enzyme inducing AEDs (phenytoin, phenobarbitone, 
primidone, and carbamazepine) are known risk factors.   
-Other AEDs including Valproate may also convey risk
Common  drug to drug 
interactions 
Carbamazepine, eslicarbazepine acetate, oxcarbazepine, 
phenobarbital, phenytoin, rufinamide, topiramate and perampanel are 
all hepatic enzyme-inducing and will impact upon contraceptive 
effectiveness (OCP) 
The interaction between lamotrigine and valproate medicines is 
important as they are a commonly used efficacious combination for 
treating generalised seizures.  Valproate influences the serum 
concentration of lamotrigine through enzyme inhibiting effects.  
Therefore in practice adding valproate or increasing the dose of 
valproate will increase lamotrigine concentrations leading to the risk of 
toxicity.  Therefore introduction of Lamotrigine in the presence of 
valproate should be done slowly and cautiously. 
Drug preparation It is advised that people prescribed certain AEDs should be maintained 
on a specific manufacturers’ product because of the risk of adverse 
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effects or loss of seizure control when changing brands of 
preparations.   
 
AEDs are grouped into three categories based on potential risk.  The 
categories, which are based on: 1. therapeutic index, 2. solubility and, 
3. absorption, should be borne in mind when prescribing   
 




Selective Serotonin Reuptake Inhibitors (SSRIs) are considered the 
first line antidepressant option in patients with epilepsy 
Older Tricyclic antidepressants have been shown to have    
pro-convulsive effect, especially  at high doses 
Psychosis  
First-generation antipsychotics may have a marginally higher seizure 
risk than second-generation antipsychotics 
Clozapine, chlorpromazine, loxapine, depot antipsychotics are 
associated with highest seizure risk.  Aripiprazole was found to have 





The dose and bioavailability of AEDs is essential to maintaining good 
seizure control [40].   
Measurement of serum concentrations of AEDs is of value, where 
there is risk of pharmacokinetic variability [41].  Clinicians should 
ensure that bioequivalence data is available for formulations and liaise 




Table 4 provides a summary of the current evidence base for the use of commonly prescribed AEDs 
specific to people with epilepsy and ID.  It is clear that there is a lack of robust randomised controlled 
trials specific to this population.  There are a number of challenges facing investigators when 
developing trial designs for people with epilepsy and ID-including recruitment, co sent, and ethical 
considerations.  However, we have evidenced the need for such robust evidence for this 
heterogeneous population in order to ensure that they receive the most appropriate and efficacious 
treatment with minimum adverse effects.  In order to improve the evidence base it is important that 
clinicians with specialist expertise in working with people with epilepsy and ID are involved is 
deigning study protocols that are flexible.  This may lead to more pragmatic investigations that are 
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applicable to real world clinical practice, focusing on AEDs with an establi hed safety and efficacy 
evidence in the general population. 
Clinician’s should work collaboratively with patients and their families or care givers to provide 
individualised treatment.  However, this approach must be guided by an evidence base.  Attempting to 
develop shared treatment goals or outcomes measures can be challenging, particularly if individuals 
have cognitive deficits, impaired communication, and unstable social environments.  There is a 
specific role within this collaboration for the clinician to hold expertise in the prescribing and 
monitoring of AEDs.  In order to do so those working with people with epilepsy and ID need to hold 
knowledge of AED prescribing and its evidence base in the general population as a baseline.  This 
article serves to add further specific information regarding common AEDs and their utility in epilepsy 
and ID based on the evidence base and consensus expert opinion. 
The Traffic Light System for AEDs should be considered a guide to prescribing clinicians when 
making treatment choices.  Allocation has been weighted by the evidence base over opinion.  There is 
no suggestion that because an AED is given  an “Amber” recommendation that it would not be the 
most appropriate choice for an individual.  Many AEDs are widely used in clinical practice regularly 
with positive outcomes, however they lack a specific evidence base for their use in people with 
epilepsy and ID.  The Traffic Light Coding will be reviewed regularly (2 yearly) and updated 
accordingly as and when new published data is available. With developing evidence it is probable to 
consider having different traffic light coding systems for Efficacy, Effects on M od, Effects on 





































• The clinical guideline provides a practical approach to medical treatment 
for people with epilepsy and intellectual disability. 
• The current evidence base has been used alongside expert clinical 
opinion to develop a user friendly ‘traffic light’ coding system for 
common antiepileptic drugs. 
• Other factors which may influence drug choice are highlighted to ensure 
treatment is individualised. 
• People with epilepsy and intellectual disability are a complex and diverse 
population with a wide range of co-morbid influencing factors that 
require consideration. 
• The current evidence base for the efficacy and tolerability of antiepileptic 
drugs in the intellectual disability population is limited and robust 
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